ResMed Inc. (RMD) Insider Sells $236,012.68 in Stock
ResMed Inc. (NYSE:RMD) insider David Pendarvis sold 2,804 shares of ResMed stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $84.17, for a total value of $236,012.68. Following the sale, the insider now directly owns 97,257 shares in the company, valued at approximately $8,186,121.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
David Pendarvis also recently made the following trade(s):
- On Friday, November 3rd, David Pendarvis sold 6,364 shares of ResMed stock. The shares were sold at an average price of $82.20, for a total value of $523,120.80.
- On Tuesday, October 3rd, David Pendarvis sold 6,364 shares of ResMed stock. The shares were sold at an average price of $76.94, for a total value of $489,646.16.
Shares of ResMed Inc. (NYSE:RMD) traded up $0.78 during trading hours on Tuesday, reaching $84.35. The company had a trading volume of 588,407 shares, compared to its average volume of 854,959. ResMed Inc. has a 1 year low of $58.71 and a 1 year high of $87.81. The company has a market capitalization of $11,860.00, a PE ratio of 29.35, a price-to-earnings-growth ratio of 1.87 and a beta of 0.78. The company has a debt-to-equity ratio of 0.50, a quick ratio of 3.86 and a current ratio of 4.72.
ResMed (NYSE:RMD) last announced its earnings results on Thursday, October 26th. The medical equipment provider reported $0.66 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.66. ResMed had a return on equity of 21.53% and a net margin of 16.58%. The firm had revenue of $523.66 million for the quarter, compared to analysts’ expectations of $506.08 million. During the same quarter in the previous year, the company earned $0.62 earnings per share. The firm’s quarterly revenue was up 12.5% compared to the same quarter last year. equities analysts predict that ResMed Inc. will post 3 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 14th. Investors of record on Thursday, November 9th will be issued a dividend of $0.35 per share. The ex-dividend date of this dividend is Wednesday, November 8th. This represents a $1.40 annualized dividend and a yield of 1.66%. ResMed’s payout ratio is 56.68%.
A number of research firms have recently weighed in on RMD. Barclays lifted their price target on ResMed from $68.00 to $70.00 and gave the company an “underweight” rating in a report on Friday, October 27th. Credit Suisse Group cut ResMed from an “outperform” rating to a “neutral” rating in a report on Tuesday, August 8th. Jefferies Group reaffirmed a “sell” rating and set a $56.00 price target on shares of ResMed in a report on Thursday, October 12th. BMO Capital Markets lifted their price target on ResMed from $70.00 to $74.00 and gave the company a “market perform” rating in a report on Friday, October 27th. Finally, Zacks Investment Research cut ResMed from a “buy” rating to a “sell” rating in a report on Tuesday, October 24th. Four analysts have rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $67.57.
Large investors have recently made changes to their positions in the stock. Creative Planning grew its position in ResMed by 97.1% in the second quarter. Creative Planning now owns 1,671 shares of the medical equipment provider’s stock worth $130,000 after buying an additional 823 shares during the last quarter. Strs Ohio grew its position in ResMed by 2.5% in the second quarter. Strs Ohio now owns 21,436 shares of the medical equipment provider’s stock worth $1,669,000 after buying an additional 523 shares during the last quarter. NGAM Advisors L.P. grew its position in ResMed by 3.4% in the second quarter. NGAM Advisors L.P. now owns 15,507 shares of the medical equipment provider’s stock worth $1,208,000 after buying an additional 504 shares during the last quarter. Janney Montgomery Scott LLC grew its position in ResMed by 6.4% in the second quarter. Janney Montgomery Scott LLC now owns 15,459 shares of the medical equipment provider’s stock worth $1,204,000 after buying an additional 935 shares during the last quarter. Finally, Daiwa Securities Group Inc. grew its position in ResMed by 9.1% in the second quarter. Daiwa Securities Group Inc. now owns 4,200 shares of the medical equipment provider’s stock worth $327,000 after buying an additional 350 shares during the last quarter. 62.02% of the stock is currently owned by hedge funds and other institutional investors.
ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.
Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.